Currently Viewing:
Newsroom
Currently Reading
Combining Local Peripheral Treatment With Ipilimumab Doubles Survival in Melanoma
July 28, 2016 – Surabhi Dangi-Garimella, PhD
Flatiron's EHR Platform for OCM Participants Promises to Foster Value-Based Care
July 28, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: Few Hospitals Receive 5 Stars in Medicare's New Ratings
July 28, 2016 – AJMC Staff
Patient Access to Reference Pricing Prompts Choice of Lower-Cost Testing Laboratories, Cost Savings
July 27, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: UnitedHealth, Aetna Plan to Join California's Medicaid Program
July 27, 2016 – AJMC Staff
Breakthrough for Daratumumab for Use as Second Line With Standard of Care in Multiple Myeloma
July 26, 2016 – Surabhi Dangi-Garimella, PhD
Former Lead of Aetna's Oncology Program, Dr Michael Kolodziej, Joins Flatiron Health
July 25, 2016 – AJMC Staff
California Experiment Will Let Pathologists Report Cancer Diagnoses in Real Time
July 25, 2016 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care July 23, 2016
July 23, 2016

Combining Local Peripheral Treatment With Ipilimumab Doubles Survival in Melanoma

Surabhi Dangi-Garimella, PhD
A new study has found that combining ipilimumab with local peripheral treatments such as radiotherapy or electrochemotherapy can significantly better survival in patients with melanoma.
Ipilimumab (Yervoy) was the first immune checkpoint inhibitor approved in oncology that revolutionized cancer treatment and significantly improved survival in patients with advanced melanoma. Now, a new study has found that combining ipilimumab with local peripheral treatments (LPT) such as radiotherapy or electrochemotherapy can significantly better survival in patients with melanoma.

Researchers at the Center of Integrated Oncology at the University Hospital of Cologne, Germany, analyzed data from 127 patients with malignant melanoma who were treated consecutively at 4 cancer centers in Germany and Switzerland. Of those, 82 were treated with ipilimumab as single agent and 45 received treatment with ipilimumab and LPT to relieve tumor-related symptoms.

Patients who received LPT in addition to the immune treatment had significantly better overall survival (OS): their median OS was 93 weeks compared with 42 weeks in patients who were treated with the drug alone (unadjusted Hazard Ratio, 0.46; P = .0028). The researchers then eliminated patients with brain metastases from the analysis, which improved the difference in survival by a greater margin: median OS was 117 weeks in those receiving ipilimumab with LPT, compared with 46 weeks in the ipilimumab-alone cohort.  

“This survival advantage seemed to overcome even traditional risk factors of poor outcomes. This suggests that this combination could be an option for all patients with malignant melanoma, and this is being tested in ongoing prospective clinical trials,” said Sebastian Theurich, MD, the lead author of the study in a statement. “We were also able to begin to investigate the potential immunologic mechanism underlying the benefit of adding local peripheral treatment to ipilimumab,” added Theurich. “It seems that local peripheral treatments activate immune cells, which are then able to attack tumors at sites away from the local treatment site. However, we are investigating this further in prospective studies.”

The study has been published in Cancer Immunology Research.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up